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Despite all the research efforts made during the last few decades, most of the cases of families with breast cancer remain unexplained.
Mutations in BRCA1 and BRCA2, and in other breast-cancer-susceptibility genes, account for about 25% of familial breast cancer. Linkage
studies have failed to identify other breast-cancer-susceptibility genes. The selection criteria of the families, differences in the population
background, or clinical and genetic heterogeneity, among other factors, might determine the power to detect the linkage signal.We have
performed a SNP-based linkage scan with a total of 6000 SNP markers across the genome in 41 breast-cancer Spanish families, with an
average of four breast-cancer cases per family not associated with BRCA1 or BRCA2 germline mutations. In addition, we have included
three BRCA-positive families to test the power in linkage detection from a low-complexity family in which a high-penetrance mutation
segregates. We have identiﬁed three regions of interest, located on 3q25, 6q24, and 21q22. The two former regions showed a suggestive
linkage signal (HLOD scores 3.01 and 2.26, respectively), and the latter region showed a signiﬁcant linkage signal (HLOD score 3.55).
Moreover, we found that a subset of 13 families with bilateral breast cancer presented a HLOD of 3.13 on the 3q25 region. Our results
suggest that several variables must be taken into account before performing a linkage study in familial breast cancer because of the high
heterogeneity within non-BRCA1/2 families. Phenotypic and geographic homogeneity could be the most important factors.Introduction
Breast cancer (BC [MIM #114480]) is the most frequent
malignant tumor among women with approximately one
million new cases per year around the world.1 About 5%
of all BC cases are considered to be due to the segregation
of a germline mutation within a family.2 The two major
BC-susceptibility genes BRCA1 (MIM þ113705) and
BRCA2 (MIM þ600185) are estimated to be involved in
20% of familial breast cancer (FBC), whereas mutations
in other high-susceptibility genes (such as PTEN [MIM
*601728], STK11 [MIM *602216], P53 [MIM *191170]) or
in moderate BC-susceptibility genes (such as CHK2
[MIM þ604373], PALB2 [MIM *610355], or BRIP1 [MIM
*605882]) explain only about 5% of FBC.3 Thus, the
majority of these families remains unexplained, and are
known as non-BRCA1/2 families.
Several studies have revealed theheterogeneousnature of
thenon-BRCA1/2 tumors. Immunohistochemical aswell as
genomic alteration patterns can distinguish different
classeswithin them,4–6 and this classiﬁcation ismaintained
when expression analyses are performed in FBC tumors.7
Thus, this heterogeneity seems to suggest that different
susceptibility genes are involved in non-BRCA1/2 FBC.
Linkage analysis is an approach commonly used in the
search for genes responsible for monogenic diseases.
However, during the last few years, several linkage analyses
have been performed in non-BRCA1/2 families withoutThe Americsuccess, via both short tandem repeat (STR or microsatel-
lite) and SNP markers covering the whole genome.8–12
Although several candidate regions suspected to contain
BC-susceptibility genes have been described in these
studies, the LOD score values obtained for these regions
were not signiﬁcant, and the percentage of families puta-
tive linked to each region was low. In a previous study, per-
formed in 19 families from the USA, the Netherlands, and
Spain with a panel of 5000 SNP markers, we identiﬁed ﬁve
regions of interest, but only one family was putative linked
to each region.9 The small number of studied families,
differences in the population background, and (probably
the most important) the clinical and genetic heterogeneity
of families might partially explain these results. In any
case, the large number of candidate regions supports the
genetic heterogeneity within non-BRCA1/2 families and
also the likely existence of different high-penetrance genes
(HPG) for breast-cancer susceptibility, each of them
explaining a small number of families. In addition, some
authors do not rule out polygenic or recessive models as
alternative explanations,13–15 although false positive
results should not be discarded.
In the present study, we aimed to minimize some of the
effects on linkage analyses of the negative variables
explained above. We have performed a SNP-based linkage
scan by using a panel of 6000 SNP markers distributed
across the genome, in a homogeneous (geographically
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from Spain. These families presented an average of four
women affected only by breast cancer, with no blood rela-
tives affected by ovarian or male breast cancer. Moreover,
we have included one BRCA1 and two BRCA2 families to
evaluate the efﬁciency of SNP-based linkage analysis in
low-complexity families in which a high-penetrancemuta-
tion segregates. We have identiﬁed three regions of
interest, one of them in 21q22 region, which showed
a signiﬁcant linkage signal (HLOD ¼ 3.55), and the other
two in 3q25 and 6q24 regions, which showed a suggestive
linkage signal (HLOD ¼ 3.01 and 2.2, respectively). The
three regions involve a total of 15 different non-BRCA1/2
families, representing 36% of the families.
Material and Methods
Selection of Families
For this study, we selected 41 Spanish families, with an average of
four BC cases per family and no mutations in either BRCA1 or
BRCA2 genes. The families were recruited after informed consent
byﬁvedifferentagencies: SpanishNationalCancerResearchCentre
(CNIO, 8 families), Instituto Catala´n de Oncologı´a (ICO, 16 fami-
lies), Hospital Santa Creu y Sant Pau (10 families), Hospital Clinico
San Carlos (6 families), and Hospital de Cruces (1 family). Families
were selected based on the following criteria: (1) at least three
women diagnosed with breast cancer below 60 years of age, (2)
no cases of ovarian cancer or male breast cancer in a blood relative,
and (3) DNA samples available for genotyping from at least three
women affected with breast cancer. In all families, DNA from one
affected member had been screened, and mutations in either
BRCA1 or BRCA2 were ruled out through different methods,16,17
including DHPLC and direct sequencing. The presence of large
deletions and insertionswas also analyzedbyMLPA (multiplex liga-
tionprobe ampliﬁcation). Finally,DNAsamples from132members
from the 41 families were available for this study. In summary,
28 families presented three or more breast-cancer cases (with or
without other unrelated cancers), whereas in the other 13 families,
at least one female member was affected by bilateral breast cancer.
The main phenotypic features of the 41 families are shown in
Table 1. This study was approved by the Ethical Committee of the
Carlos III Health Institute.
In order to know the efﬁciency in linkage detection of the SNP
marker panel in a set of low-complexity families, we selected
15 members (carriers and noncarriers) from one BRCA1-positive
family and two BRCA2-positive families, which presented a similar
structure to the non-BRCA1/2 families included in this linkage
analysis (Figure 1). We considered mutation carriers as affected
members (complete penetrance) to calculate the HLOD score we
could expect for a single family in which a high-penetrance
mutation segregates. We calculated the HLOD score for each
BRCA-positive family by using different combinations of the gen-
otyped members (see Table S1 available online), and we selected
the maximumHLOD score value as representative of each original
BRCA-positive family. We took as references those SNP markers
ﬂanking both genes (rs1008753-rs1385 for BRCA1 and rs390704-
rs132934 for BRCA2).
Markers and Genotyping
A total of 147 individuals were genotyped with Illumina BeadAr-
ray genotyping system. We genotyped 115 individuals from 36116 The American Journal of Human Genetics 84, 115–122, Februarnon-BRCA1/2 families with the Illumina BeadArray linkage
mapping panel version IV, which consists of 6000 genome-wide
SNP markers. Another 17 individuals from 5 non-BRCA1/2 fami-
lies were genotyped with Illumina BeadArray linkage mapping
panel version III, which consists of a total of 5000 genome-wide
SNP markers, and have been reported previously.9 The 15 individ-
uals from the 3 BRCA-positive families were genotyped with the
Illumina BeadArray linkage mapping panel version IV. We
compared both linkage panels (versions III and IV) for compati-
bility and found no inconsistencies. However, in order to homog-
enize the label of the alleles to perform the whole analysis with
Merlin software, we reassigned genotypes to samples genotyped
with linkage panel III according to the probe designs in linkage
panel IV, including missing values for those SNP markers that
were not included in linkage panel III but were included in linkage
panel IV. We selected linkage panel IV because it has been
described that the linkage disequilibrium between SNP markers
with a spacing similar to linkage panel III is limited and does
not affect the linkage signal, which supports these SNP panels as
reliable tools in linkage analysis.9,18
In order to conﬁrm the familial segregation of the haplotypes
obtained with the SNP markers, we selected STR markers with
high heterozygosity, covering and ﬂanking the candidate regions,
with aminimal distance of 1 cM between each pair of STRmarkers.
Four STR markers were genotyped in those families selected as
putative linked to each of the candidate regions on both chromo-
somes 3 and 21, and another ﬁve STR markers were genotyped in
those families selected as putative linked to the candidate region
on chromosome 6. Genetic and physical information for all the
STR markers was obtained from NCBI MapViewer and is shown
in Table S2. Genotyping of the STR markers was performed with
speciﬁc primers obtained from NCBI UniSTS database and the
ABI 3700 DNA sequencer platform, and data analysis was carried
out with Genescan software. Quality control analyses were
performed with PEDSTAT and PEDCHECK programs to check
family structure, and error-detection and wipe (Merlin software
options) were used to evaluate genotyping reliability, as previously
reported.9We used CGHExplorer19 software to visualize the results
from Merlin software.
Genetic Parameters
The analysis of all families combined was performed by assuming
that all families were of the same genetic and homogeneous back-
ground, as we demonstrated in a previous stratiﬁcation study in
the Spanish population.20 For SNP analysis, we calculated the
allele frequencies considering all the genotyped individuals (ALL
frequencies). For microsatellite analysis, we genotyped an addi-
tional sample of 95 unrelated healthy Spanish individuals to
obtain better allele frequency estimates. A genetic map with








No bilaterality 14 3 0 49.13
9 4 0 51.12
5 >4 0 51.24
Bilaterality 4 3 1 48.95
9 >3 >1 50.20
Total 41 156 15 49.88y 13, 2009
Figure 1. Representation of the BRCA1/2 Families
Mutation carrier individuals (þ) were supposed to be affected members (complete penetrance) and their genotypes were used to obtain
dominant parametric LOD scores (HLOD) for each family in either chromosome 13 or chromosome 17. Genotypes from noncarriers indi-
viduals () were used to observe variations in HLOD scores. When a noncarrier individual was included as an affected member (pheno-
copy), HLOD score dropped to even negative values in the region that harbors the mutation. When a noncarrier individual is included as
a nonaffected member, the increase in HLOD score was not significant.meioses derived from CEPH pedigrees was constructed by Illu-
mina21 and used for SNP analysis. For microsatellite data, we
used the STR genetic map constructed by deCODE Genetics Inc.22
Statistical Analysis
We estimated LOD score values via Merlin software23,24 in two
different ways: (1) multipoint and singlepoint nonparametric
linkage analyses (NPL); and (2) multipoint and singlepoint para-
metric linkage analyses (HLOD) were estimated assuming a domi-
nant model based on previous publications.25 In the model, the
susceptibility allele is supposed to have a population frequency
of 0.003, and risks were modeled in 7 age categories and imple-
mented in 14 liability classes, with separate classes for
unaffected and affected individuals.26 Multipoint and singlepoint
analyses for the whole family set and for each family individually
(with the perFamily option in Merlin software) were performed
with ALL frequencies. We considered candidate linkage regions
those regions that showed NPL score with associated p value <
0.01 and HLOD score higher than 2.20 (suggestive linkage). Addi-
tional ﬁne-mapping microsatellite data was also analyzed with
Merlin software, and parametric and nonparametric analyses
were performed.
In order to evaluate the robustness of our linkage results, we
used Merlin’s simulation option to estimate empirically the prob-The Americability that the observed results could be obtained by chance. Ten
thousand genome-wide replicates were analyzed under the null
hypothesis of no linkage to breast cancer, and the number of
regions with a HLOD score over the speciﬁed threshold was deter-
mined in each genome-wide replicate.
Results
Linkage Analysis
We have performed a linkage analysis in 41 non-BRCA1/2
families with a panel of 6000 SNP markers across the
genome. The results of multipoint nonparametric (NPL)
and parametric (HLOD) analyses for all chromosomes are
shown in Figure 2. Candidate regions were determined as
those regions that showed NPL score with associated
p value< 0.01 and HLOD score higher than 2.2. According
to these criteria, we selected three regions on three
different chromosomes as regions that might contain
breast-cancer-susceptibility genes: 3q25 region with
a maximum NPL score of 2.46 (p value ¼ 0.007) and
maximumHLOD score of 3.01 (alpha ¼ 0.51); 6q24 region
with a maximum NPL score of 2.65 (p value ¼ 0.004) andFigure 2. Representation of LOD Scores for All the Autosomal Chromosomes
The y axis represents LOD score values and x axis represents the autosomal chromosomes. The green line represents the nonparametric LOD
score (NPL), whereas the blue line represents dominant parametric LOD score (HLOD) score for the 22 autosomal chromosomes. Vertical
lines represent the chromosomal boundaries.an Journal of Human Genetics 84, 115–122, February 13, 2009 117
Table 2. Maximum LOD Scores in the Three Candidate Regions
From To
Chromosome Region SNP Mb SNP Mb Families NPL (Max) p Value HLOD (Max)
3 q25.33-q26.2 rs1472578 160.29 rs1920122 170.98 6(6) 2.46 0.007 3.01
6 q24.3-q25.1 rs612928 144.64 rs1407491 153.03 7(5) 2.65 0.004 2.26
21 q22.13 rs1012959 36.98 rs2836301 38.59 5(5) 4.37 0.00001 3.55
Nonparametric (NPL) and parametric (HLOD) LOD scores obtained from the whole set of 41 families for the three candidate regions. The number of putative
linked families is shown before and after fine-mapping strategy. In bold and italics is shown the significant HLOD value for chromosome 21.maximumHLOD score of 2.26 (alpha ¼ 0.501); and 21q22
region with a maximum NPL score of 4.37 (p value ¼
0.00001) and maximum HLOD score of 3.55 (alpha ¼
0.751). The size of the regions was about 10 Mb for the
regions on both chromosomes 3 and 6, and about 2 Mb
for the region on chromosome 21. All the information of
the candidate regions is summarized in Table 2.
We wanted to know the power that the SNP panel has to
detect the linkage signal in low-complexity families;
furthermore, we included three families with knownmuta-
tions in either BRCA1 or BRCA2 genes in this study
(Figure 1). Therefore, we performed parametric linkage
analysis in a set of different combinations of the genotyped
members for each family, andwe calculated theHLODscore
for every single combination (see Table S1). We observed
that the maximum HLOD score from BRCA-positive fami-
lies data varied from 0.26 to 0.62, for a single family
(Figure 1). HLOD score was calculated for each of the 41
non-BRCA1/2 families, and, in order to avoid a high rate
of false-positive results, we determined those families that
showed HLOD score ~0.50 as putative linked families to
each candidate region. We observed that even in a family
in which a high-penetrance mutation segregates, the
HLOD score depended on the genotyped members used
to calculate it (genotypical dependence, see Table S1). We
also observed that the HLOD score decreased even to nega-
tive values when a noncarrier individual was labeled as
affected (phenocopy effect, see Table S1).
We selected six families for chromosome 3, seven fami-
lies for chromosome 6, and ﬁve families for chromosome
21 as putative linked families, with HLOD scores ranging
from 0.46 to 1.28. Two families showed a similar linkage
signal in both chromosomes 3 and 6, and another family
showed a similar linkage signal in both chromosomes 3
and 21. Finally, these 15 different families were included
for the next step, the ﬁne-mapping strategy via STR
markers, and the clinical features of these families are
shown in Table 3.
Simulation Study
In order to examine the false positive rates in our data, we
generated 10,000 random genome-wide scan replicates of
the data via Merlin software, and we calculated how many
genome-wide scans with a maximum HLODR 3.60 could
be expected by chance. We calculated the number of repli-
cates with a maximum HLOD score higher than or equal118 The American Journal of Human Genetics 84, 115–122, Februarto 3.60, because this is the threshold for signiﬁcant linkage
estimated for STR markers.27 We observed that only 155
replicate scans showed HLODR 3.60, giving an empirical
p value of 0.015. The empirical threshold for signiﬁcance
was HLOD > 3.10 (p value ¼ 0.05).
Fine Mapping Strategy
In order to conﬁrm or rule out the haplotypical segregation
in our candidate families, we performed the additional
genotyping of a panel of high-heterozygosity STR markers
in the three candidate regions (Table S2). We analyzed
a total of 13 STR markers (four STR markers in both chro-
mosomes 3 and 21 and ﬁve STRmarkers in chromosome 6)
in those families putative linked to each candidate region.
We calculated the HLOD score by using Merlin software,
for both SNP and STR markers (Table 4). The HLOD score
of the candidate regions in both chromosomes 3 and 21
was maintained or even increased (conﬁrming the haplo-
typical segregation of both SNP and STR markers in all
the families putative linked to these regions), whereas
the impact of ﬁne-mapping in the candidate region on
chromosome 6 was evident as the HLOD score fell from
4.93 (SNP markers) to 3.40 (SNPþSTR markers). The
Table 3. Clinical Features of the Linked Families for Each
Candidate Region









3 3q25 3 4 1 47.4
5 7 1 50.3 lymphoma
10 8 1 52.8 leukemia
21 3 0 50.3 colon
27 4 0 47.5 gastric
24 6 1 59.5 lymphoma
6 6q24 2 4 0 38.2 thyroid
6 5 1 51.1 bladder
31 3 0 43.1 CNS/CRCa
33 5 0 50.8
35 4 0 49.2
21 21q22 8 3 2 46.7 colon
9 4 0 40.7
18 4 1 46.1
41 4 0 51.5
24 6 1 59.5 lymphoma
Family 24 was confirmed as linked to both chromosome 3 and 21 candidate
regions.
a CNS, central nervous system tumor; CRC, colorectal cancer.y 13, 2009
Table 4. Maximum HLOD Scores in the Three Candidate Regions via SNP and STR Markers
From To
Chromosome Region SNP Mb SNP Mb HLOD SNPs HLOD SNPs þ FM STRs
3 q25.33-q26.2 rs1472578 160.29 rs905129 172.43 5.33 5.46
6 q24.3-q25.1 rs612928 144.64 rs1407491 153.03 4.93/3.33 3.40/3.39
21 q22.11-q22.13 rs762173 32.75 rs2836301 38.59 3.57 3.68
Parametric (HLOD) LOD scores obtained from the candidates families for the three candidate regions before and after fine-mapping. In chromosome 6, HLOD
score is shown for the seven initial putative linked families and the five final putative linked families. The three regions were confirmed after fine-mapping.decrease in the HLOD score on this region may be ex-
plained by the fact that there was no segregation of STR
markers in the two families putative linked to both chro-
mosomes 3 and 6, even though the haplotypical segrega-
tion with both SNP and STR markers was conﬁrmed in
chromosome 3. When these two families were removed
from the data set in chromosome 6, the HLOD score
increased from 3.33 (SNP markers) to 3.39 (SNPþSTR
markers). Only the haplotypical segregation of family 24
was conﬁrmed in both chromosomes 3 and 21 after micro-
satellite data analysis. Figure S1 represents how STR
markers allowed us to conﬁrm (Figure S1A) or to rule out
(Figure S1B) the haplotypical segregation in two candidate
families identiﬁed by SNP markers as putative linked to
chromosome 6. These results support the ﬁne-mapping
strategy as a useful haplotype validation tool in linkage
studies. Thus, we corroborated the three chromosomal
regions to be candidates to harbor breast-cancer-suscepti-
bility genes, although no informative recombination
events were found and we were not able to narrow down
the size of the regions.
Subgroup Analysis
Weobserved that the regions on both chromosomes 21 and
3, which showed the highest HLOD scores, were associated
with a higher number of affected cases per family (4.7 cases
versus 3.8 cases, p value< 0.05) and a higher percentage of
bilaterality (14.9% versus 6.9%, p value < 0.04). Moreover,
we observed that families linked to chromosome 6 had an
earlier age of onset on average, although not signiﬁcant
(46.6 years versus 50.37 years, p value¼ 0.20) (see Table 3).
According to these data,wehave calculated theHLODscore
for those families that presented cases affected by bilateral-
ity (13 families), for those that presentedmore than 4 cases
(23 families), and for those families with a mean age less
than or equal to 50 years (21 families). Themost interesting
result was that the subset of families with bilaterality
showed a HLOD ¼ 3.13 for region on chromosome 3, but
no linkage signal to either chromosome 21 or chromo-
some 6 (Table S3).
Discussion
In the present linkage study performed across 41 Spanish
non-BRCA1/2 families, signiﬁcant linkage signal wasThe Americobserved for one candidate region on chromosome 21
(HLOD score 3.55), with 5 (12.2%) families linked, and
suggestive linkage signal was observed for candidate
regions on both chromosomes 3 and 6 (HLOD score¼ 3.01
and 2.26, respectively) with 6 (14.6%) and 5 (12.2%) fami-
lies putative linked, respectively. These results suggest the
presence of several putative HPG for breast cancer and
each one could explain a low percentage of multiple-case
families.
To date, numerous linkage studies have been performed
on families with breast cancer,8–12 identifying different
candidate regions, which showed no signiﬁcant or sugges-
tive LOD scores. In addition, and probably due to the small
number of families in some cases, geographic differences,
or clinical and genetic heterogeneity of the families in
others, none of the candidate regions have been conﬁrmed
in a new series of non-BRCA1/2 families. Similarly, our
group performed a previous SNP-based linkage study,
which included 19 families from the USA, the Netherlands,
and Spain.9 We identiﬁed ﬁve candidate regions on ﬁve
different chromosomes, but only one family was linked
to each region. These results suggested that heterogeneity
among families from different geographic areas could
mask linkage signal, especially when the number of fami-
lies is small.
Because of this fact, we decided to perform a new SNP-
based linkage analysis including a more homogeneous
(phenotypically and geographically) set of families of 41
Spanish non-BRCA1/2 breast-cancer families from a non-
stratiﬁed population,20 with an average of 4 females
affected only by breast cancer (Table 1). None of the
regions described previously were validated in the present
study and, vice versa, none of the three regions described
in the present study were found in previous studies.
Furthermore, all these data might suggest population
speciﬁcity, although we cannot discard the effect of
randomness.
In order to know the HLOD score to be expected from
a low-complexity family in which a HPG segregates, we
included three families with known mutations in either
BRCA1 or BRCA2 genes and similar familial structure to
our non-BRCA1/2 families. We found that these families
presented a maximum HLOD score between 0.26 and
0.62 (Figure 1), suggesting that a high amount of informa-
tion could be missed if we applied the standard thresholds
of 1.5, established in high-complexity families.11 Thus, wean Journal of Human Genetics 84, 115–122, February 13, 2009 119
decided to select those families that showed a HLOD score
around 0.50 as families putative linked to each region,
resulting in a total of 15 different families being selected
for the three regions (Table 2). We corroborated the linkage
signal in these regions by using a panel of STR markers,
which covered and ﬂanked the candidate regions. We
also ruled out the haplotypical segregation of two families
putative linked to chromosome 6 with microsatellite data,
although these families segregated in both chromosomes 3
and 6 with SNP markers and were conﬁrmed in chromo-
some 3. Finally, we considered 6 families as putative linked
to 3q25 region, 5 families to 6q24 region, and 5 families to
21q22 region (Table 4).
Wealso analyzedwhether the thresholds estimatedwhen
genome-wide scans were based on STR markers27 were reli-
able or not for genome-wide scans based on high-density
maps of low-heterozygosity markers. Furthermore, we
generated 10,000 random genome-wide scan replicates of
the data and we observed that the probability of ﬁnding
HLOD scores greater than 3.60 was signiﬁcant (empirical
p value ¼ 0.015). This result supports the use of the estab-
lished thresholds for SNPmarkers aswell as for STRmarkers.
Our results highlight different factors that may affect
linkage studies in FBC. Probably themost important points
for consideration is the genetic heterogeneity among non-
BRCA1/2 families and also the genetic heterogeneity
among human populations. The regions described during
the past few years as genomic areas potentially harboring
HPG for breast cancer and those found in the present
report are represented in Table 5. Only those regions asso-
ciated with either a single big family or a small group of
families that presented HLOD scores R1.5 are included
in this table. These two groups probably represent the
scenario in which non-BRCA1/2 families could be repre-
sented, e.g., various susceptibility genes and each of
them explaining a low number of families. In addition,
an important characteristic that in some cases may be
observed is the linkage signal of a single family to two or
three different regions. In these cases, the probability
that two HPGs are segregating together through different
generations is very low. An example of this fact is a family
we previously studied, which was linked to both chromo-
somes 11 and 14 (see Table 5, FAM153). We calculated
the probability that the four studied members share two
loci by chance in 1/540,000 (unpublished data). Further-
more, we can discard neither that only one, or even
none, of these regions contain a causal gene, nor that
two moderate-penetrance genes interact among them or
with other low-penetrance genes.
Although we cannot quantify the percentage of non-
BRCA1/2 families that could be explained by the candidate
regions in Table 5, it is likely to be less than 0.10 per region.
Data from the study conducted by the BCLC11 estimated
0.18 as the proportion of families that would be explained
by those genes included in the regions on both chromo-
somes 2 and 4, and 0.06 as the proportion of families
that would be explained by those genes included in the120 The American Journal of Human Genetics 84, 115–122, Februarregion on chromosome 22. In our study, we estimated in
0.36 (15/41 families) the proportion of families that might
be explained by genes located on the three regions: 0.12 (5/
41 families) for both chromosomes 6 and 21, and 0.14 (6/
41 families) for chromosome 3. Although these results can
be biased by possible false positive cases, they could
support the idea that there are many HPGs involved in
familial breast cancer, probably associated with subsets of
homogeneous populations or with common phenotypic
features. In this way, it is important to highlight the asso-
ciation between the 2p21 region and the group of families
with more than four breast cancer cases (LOD ¼ 2.4)
pointed out by the BCLC.11 In our study, we have found
a similar result with a subset of families with bilateral
breast cancer. This group presented a unique linkage signal
on chromosome 3q25 (HLOD¼ 3.13), which represents an
interesting association for further studies.
In summary, we consider that, in order to achieve greater
power, future linkage studies should contemplate the
possibility of studying sets of families with more homoge-
neous features, phenotypical and/or geographical, instead
of large studies with heterogeneous sets of families. In
addition, we think that it is important to include low-
complexity pedigrees of BRCA1/2 families as an internal
control, in order to consider the new LOD score thresholds
that can be expected instead of the classical thresholds
Table 5. Summary of the Studies Performed in Non-BRCA1/2
Families during the Last Years
Study Center Family Chr. Region LOD score
[11] Australia 699003 2 2p21 1.67
IARC 2191 4 4p14-q12 1.84a
20 20q13.1 1.80
MAYO151 3 3p14 1.52
11 11p13 1.59
Netherlands RUL153 11 11q14 1.67b
UK EUR60a 15 15q14 1.50
EUR60b 4 4q13.1-q13.2 1.91
22 22q13.2 2.62
[10] Finland 2 2q32 1.61
[8] Sweden Family 14 10 10q23 1.66
19 19q13 1.52
17 17p13 1.51
[9] CNIO FAM3395 2 2p22.3 1.92
FAM2191 4 4p14q12 1.8a
FAM153 11 11q13.5q14.3 2.2b
14 14q21.1q21.3 2.2
Present study Spain 6 families 3 3q25-33 3.01
5 families 6 6q24 2.26
5 families 21 21q22.13 3.55
In order to make possible a complete comparison between the studies,
chromosomal regions for the study reported in [11] have been estimated
from genetic distances associated with STR markers presented by the
authors. LOD scores were performed with the same dominant model adapted
by authors of [26] in all the studies.
a Same family studied.
b Same family studied.y 13, 2009
based on high-complexity BRCA1/2 pedigrees. This
strategy could probably permit the identiﬁcation of puta-
tive candidate regions associated with homogeneous
groups of families.
Supplemental Data
Supplemental Data include one ﬁgure and three tables and can be
found with this article online at http://www.ajhg.org/.
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